UA79091C2 - Liquid polymer composition for prevention and treatment of the oral cavity diseases - Google Patents
Liquid polymer composition for prevention and treatment of the oral cavity diseases Download PDFInfo
- Publication number
- UA79091C2 UA79091C2 UA20031210980A UA20031210980A UA79091C2 UA 79091 C2 UA79091 C2 UA 79091C2 UA 20031210980 A UA20031210980 A UA 20031210980A UA 20031210980 A UA20031210980 A UA 20031210980A UA 79091 C2 UA79091 C2 UA 79091C2
- Authority
- UA
- Ukraine
- Prior art keywords
- therapeutic agent
- composition
- alcohol
- mixed
- polymeric material
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 239000007788 liquid Substances 0.000 title claims abstract description 15
- 201000010099 disease Diseases 0.000 title claims abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 10
- 210000000214 mouth Anatomy 0.000 title claims abstract description 5
- 230000002265 prevention Effects 0.000 title claims description 4
- 229920000642 polymer Polymers 0.000 title description 21
- 239000003814 drug Substances 0.000 claims abstract description 68
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 56
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 32
- 239000000463 material Substances 0.000 claims abstract description 22
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 14
- 229920001577 copolymer Polymers 0.000 claims abstract description 12
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 claims abstract description 12
- 230000001476 alcoholic effect Effects 0.000 claims abstract description 9
- 210000004268 dentin Anatomy 0.000 claims abstract description 7
- 239000011698 potassium fluoride Substances 0.000 claims abstract description 6
- 235000003270 potassium fluoride Nutrition 0.000 claims abstract description 6
- 159000000007 calcium salts Chemical class 0.000 claims abstract description 5
- 239000004014 plasticizer Substances 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 230000008020 evaporation Effects 0.000 claims abstract description 3
- 238000001704 evaporation Methods 0.000 claims abstract description 3
- 159000000008 strontium salts Chemical class 0.000 claims abstract description 3
- 150000003751 zinc Chemical class 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 claims description 31
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 12
- 239000003242 anti bacterial agent Substances 0.000 claims description 10
- 239000008213 purified water Substances 0.000 claims description 8
- 239000011592 zinc chloride Substances 0.000 claims description 6
- 235000005074 zinc chloride Nutrition 0.000 claims description 6
- 239000002861 polymer material Substances 0.000 claims description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 4
- 229960004150 aciclovir Drugs 0.000 claims description 4
- 239000001110 calcium chloride Substances 0.000 claims description 4
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 4
- 229960002152 chlorhexidine acetate Drugs 0.000 claims description 4
- 229960005264 piperacillin sodium Drugs 0.000 claims description 4
- 229910001631 strontium chloride Inorganic materials 0.000 claims description 4
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- 229960002798 cetrimide Drugs 0.000 claims description 3
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical group [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- ZXBDZLHAHGPXIG-VTXLJDRKSA-N (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione;(2r,3 Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ZXBDZLHAHGPXIG-VTXLJDRKSA-N 0.000 claims description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 2
- GTNDZRUWKHDICY-DJHAJVGHSA-N Clindamycin palmitate hydrochloride Chemical compound Cl.O1[C@H](SC)[C@H](OC(=O)CCCCCCCCCCCCCCC)[C@@H](O)[C@@H](O)[C@H]1[C@@H]([C@H](C)Cl)NC(=O)[C@H]1N(C)C[C@H](CCC)C1 GTNDZRUWKHDICY-DJHAJVGHSA-N 0.000 claims description 2
- 229940090898 Desensitizer Drugs 0.000 claims description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 2
- 229960003805 amantadine Drugs 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 2
- 229960001950 benzethonium chloride Drugs 0.000 claims description 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 claims description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 2
- 229960003669 carbenicillin Drugs 0.000 claims description 2
- RTYJTGSCYUUYAL-YCAHSCEMSA-L carbenicillin disodium Chemical compound [Na+].[Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)C(C([O-])=O)C1=CC=CC=C1 RTYJTGSCYUUYAL-YCAHSCEMSA-L 0.000 claims description 2
- QFWPXOXWAUAYAB-XZVIDJSISA-M carindacillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)C(C(=O)OC=1C=C2CCCC2=CC=1)C1=CC=CC=C1 QFWPXOXWAUAYAB-XZVIDJSISA-M 0.000 claims description 2
- XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 claims description 2
- OYSKUZDIHNKWLV-PRUAPSLNSA-N clindamycin palmitate Chemical compound O1[C@H](SC)[C@H](OC(=O)CCCCCCCCCCCCCCC)[C@@H](O)[C@@H](O)[C@H]1[C@@H]([C@H](C)Cl)NC(=O)[C@H]1N(C)C[C@H](CCC)C1 OYSKUZDIHNKWLV-PRUAPSLNSA-N 0.000 claims description 2
- 229960004714 clindamycin palmitate Drugs 0.000 claims description 2
- 229960000792 clindamycin palmitate hydrochloride Drugs 0.000 claims description 2
- 229960003026 cloxacillin sodium Drugs 0.000 claims description 2
- SCLZRKVZRBKZCR-SLINCCQESA-M cloxacillin sodium Chemical compound [Na+].N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C([O-])=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl SCLZRKVZRBKZCR-SLINCCQESA-M 0.000 claims description 2
- 229960005194 erythromycin gluceptate Drugs 0.000 claims description 2
- 229960004213 erythromycin lactobionate Drugs 0.000 claims description 2
- 229960004273 floxacillin Drugs 0.000 claims description 2
- PARMJFIQRZRMHG-VICXVTCVSA-M flucloxacillin sodium monohydrate Chemical compound O.[Na+].N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C([O-])=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl PARMJFIQRZRMHG-VICXVTCVSA-M 0.000 claims description 2
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 claims description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 2
- 229960004023 minocycline Drugs 0.000 claims description 2
- 229960001775 nafcillin sodium Drugs 0.000 claims description 2
- OCXSDHJRMYFTMA-KMFBOIRUSA-M nafcillin sodium monohydrate Chemical compound O.[Na+].C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C([O-])=O)=O)C(OCC)=CC=C21 OCXSDHJRMYFTMA-KMFBOIRUSA-M 0.000 claims description 2
- 239000004302 potassium sorbate Substances 0.000 claims description 2
- 229940069338 potassium sorbate Drugs 0.000 claims description 2
- 235000010241 potassium sorbate Nutrition 0.000 claims description 2
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 claims description 2
- AHBGXTDRMVNFER-UHFFFAOYSA-L strontium dichloride Chemical compound [Cl-].[Cl-].[Sr+2] AHBGXTDRMVNFER-UHFFFAOYSA-L 0.000 claims description 2
- 229960004989 tetracycline hydrochloride Drugs 0.000 claims description 2
- 229940033663 thimerosal Drugs 0.000 claims description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims description 2
- RPLOPBHEZLFENN-HTMVYDOJSA-M sodium;4-[(2r,3r)-2-[(2,2-dichloroacetyl)amino]-3-hydroxy-3-(4-nitrophenyl)propoxy]-4-oxobutanoate Chemical compound [Na+].[O-]C(=O)CCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 RPLOPBHEZLFENN-HTMVYDOJSA-M 0.000 claims 2
- ZOEGVPMIKKQYKQ-FJGDRVTGSA-N 1-[(2r,3r,4s,5r)-2,3,4-trihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@@]1(O)N1C(=O)NC(=O)C=C1 ZOEGVPMIKKQYKQ-FJGDRVTGSA-N 0.000 claims 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims 1
- 229960004357 chloramphenicol succinate Drugs 0.000 claims 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims 1
- POUMFISTNHIPTI-BOMBIWCESA-N hydron;(2s,4r)-n-[(1r,2r)-2-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide;chloride Chemical compound Cl.CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 POUMFISTNHIPTI-BOMBIWCESA-N 0.000 claims 1
- 229960001595 lincomycin hydrochloride Drugs 0.000 claims 1
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- 230000035515 penetration Effects 0.000 abstract description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- 229920003134 Eudragit® polymer Polymers 0.000 abstract 4
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 abstract 4
- 238000000586 desensitisation Methods 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 13
- 208000005888 Periodontal Pocket Diseases 0.000 description 12
- 230000003239 periodontal effect Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 7
- 208000028169 periodontal disease Diseases 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000011161 development Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 210000005239 tubule Anatomy 0.000 description 5
- 239000000853 adhesive Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 229920006254 polymer film Polymers 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 229920000249 biocompatible polymer Polymers 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- -1 dextran) Chemical class 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000001103 potassium chloride Substances 0.000 description 3
- 235000011164 potassium chloride Nutrition 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- LIRCDOVJWUGTMW-ZWNOBZJWSA-N Chloramphenicol succinate Chemical compound OC(=O)CCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 LIRCDOVJWUGTMW-ZWNOBZJWSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960002579 chloramphenicol sodium succinate Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 125000005395 methacrylic acid group Chemical group 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 201000001245 periodontitis Diseases 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010061728 Bone lesion Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 206010052359 Gingival abscess Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- APGWYVPXCFOREW-HOCYRETQSA-N I[C@@]1([C@H](O)[C@H](O)[C@@H](C(O)=O)O1)N1C(=O)NC(=O)C=C1 Chemical compound I[C@@]1([C@H](O)[C@H](O)[C@@H](C(O)=O)O1)N1C(=O)NC(=O)C=C1 APGWYVPXCFOREW-HOCYRETQSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000001277 chronic periodontitis Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 239000005548 dental material Substances 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- 229960000878 docusate sodium Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 210000003731 gingival crevicular fluid Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940126702 topical medication Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0063—Periodont
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01112751A EP1262172A1 (en) | 2001-05-25 | 2001-05-25 | Liquid polymer composition for prevention and treatment of the oral cavity diseases |
| PCT/EP2002/005728 WO2002098464A2 (en) | 2001-05-25 | 2002-05-24 | Liquid polymer composition for prevention and treatment of the oral cavity diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA79091C2 true UA79091C2 (en) | 2007-05-25 |
Family
ID=8177549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA20031210980A UA79091C2 (en) | 2001-05-25 | 2002-05-24 | Liquid polymer composition for prevention and treatment of the oral cavity diseases |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20040126333A1 (bg) |
| EP (2) | EP1262172A1 (bg) |
| AT (1) | ATE533511T1 (bg) |
| BG (1) | BG108480A (bg) |
| CZ (1) | CZ20033541A3 (bg) |
| HR (1) | HRP20031016A2 (bg) |
| HU (1) | HUP0401308A2 (bg) |
| PL (1) | PL366903A1 (bg) |
| RU (1) | RU2301056C2 (bg) |
| SK (1) | SK15832003A3 (bg) |
| UA (1) | UA79091C2 (bg) |
| WO (1) | WO2002098464A2 (bg) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005050654A1 (de) * | 2005-10-20 | 2007-04-26 | LABTEC Gesellschaft für technologische Forschung und Entwicklung mbH | Lippenpflaster |
| US8512761B2 (en) | 2006-01-27 | 2013-08-20 | Yale University | Fast acting inhibitor of gastric acid secretion |
| EP1976532B1 (en) * | 2006-01-27 | 2015-11-11 | Yale University | Fast acting inhibitor of gastric acid secretion |
| WO2009098531A1 (en) * | 2008-02-07 | 2009-08-13 | Italmed S.R.L. | Dental composition for desensitization and disinfection of exposed dentin |
| ITPI20080025A1 (it) * | 2008-03-31 | 2009-10-01 | Italmed S R L | Composizione ad uso odontoiatrico per il trattamento delle perimplantiti |
| US9504698B2 (en) | 2009-10-29 | 2016-11-29 | Warsaw Orthopedic, Inc. | Flowable composition that sets to a substantially non-flowable state |
| US20150342839A1 (en) | 2010-04-21 | 2015-12-03 | Oraceutica LLC | Compositions and methods for whitening teeth |
| RU2012149460A (ru) | 2010-04-21 | 2014-05-27 | ДИСКУС ДЕНТАЛ, ЭлЭлСи | Способ одновременной чистки и отбеливания зубов |
| RU2427379C1 (ru) | 2010-09-20 | 2011-08-27 | Закрытое акционерное общество "Институт прикладной нанотехнологии" | Состав для профилактики и ухода за диабетической стопой |
| US8888489B2 (en) | 2012-10-23 | 2014-11-18 | Oraceutical Llc | Method of simultaneously cleaning and whitening teeth |
| US9549930B2 (en) | 2013-03-14 | 2017-01-24 | Quadex Pharmaceuticals, Llc | Combined systemic and topical treatment of disordered and/or prodromal stage tissue |
| US9125911B2 (en) | 2013-03-14 | 2015-09-08 | Quadex Pharmaceuticals, Llc | Combined systemic and topical treatment of disordered tissues |
| US9463180B2 (en) | 2013-03-14 | 2016-10-11 | Quadex Pharmaceuticals, Llc | Treatment of molluscum contagiosum |
| US9320580B2 (en) | 2013-04-21 | 2016-04-26 | Oraceutical Llc | Hand-held tooth whitening instrument with applicator reservoir for whitening composition and methods of using same |
| RU2662305C2 (ru) * | 2013-09-11 | 2018-07-25 | 3М Инновейтив Пропертиз Компани | Композиции для полости рта, стоматологические конструктивные элементы и способы доставки композиций для полости рта |
| WO2015038400A1 (en) | 2013-09-11 | 2015-03-19 | 3M Innovative Properties Company | Oral compositions |
| CN105997847A (zh) * | 2016-06-24 | 2016-10-12 | 昆明悟真生物科技有限公司 | 一种抑菌凝胶 |
| RU2729058C2 (ru) * | 2018-08-23 | 2020-08-04 | федеральное государственное автономное образовательное учреждение высшего образования "Российский университет дружбы народов" (РУДН) | Способ предупреждения развития вторичного кариеса |
| IT201900018752A1 (it) * | 2019-10-14 | 2021-04-14 | Alessandro Tosetti | Composizione a base di olii essenziali ad uso odontoiatrico per il trattamento della periodontite e della mucosite perimplantare |
| CN111841454B (zh) * | 2020-06-19 | 2022-07-05 | 山西振东泰盛制药有限公司 | 注射用氟氯西林钠凝胶微球、制备装置及其制备方法 |
| CN112076221B (zh) * | 2020-09-24 | 2022-02-22 | 四川天福精细化工有限公司 | 一种脱敏糊剂及其制备方法和用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4701320A (en) * | 1984-11-29 | 1987-10-20 | Lederle (Japan), Ltd. | Composition stably containing minocycline for treating periodontal diseases |
| US5160737A (en) * | 1988-05-03 | 1992-11-03 | Perio Products Ltd. | Liquid polymer composition, and method of use |
| DE3822095A1 (de) * | 1988-06-30 | 1990-01-04 | Klinge Co Chem Pharm Fab | Neue arzneimittelformulierung sowie verfahren zu deren herstellung |
| DE4125048A1 (de) * | 1991-07-29 | 1993-02-04 | Peggy Albrecht | Arzneimittel mit verzoegerter freisetzung zur behandlung von periodontitis |
| EP1021204B1 (en) * | 1997-09-26 | 2005-12-28 | Noven Pharmaceuticals, Inc. | Bioadhesive compositions and methods for topical administration of active agents |
| KR20010075053A (ko) * | 1999-07-12 | 2001-08-09 | 도리이 신이찌로 | 국소 투여용 의약 조성물 |
-
2001
- 2001-05-25 EP EP01112751A patent/EP1262172A1/en not_active Withdrawn
-
2002
- 2002-05-24 SK SK1583-2003A patent/SK15832003A3/sk not_active Application Discontinuation
- 2002-05-24 AT AT02754586T patent/ATE533511T1/de active
- 2002-05-24 WO PCT/EP2002/005728 patent/WO2002098464A2/en not_active Application Discontinuation
- 2002-05-24 CZ CZ20033541A patent/CZ20033541A3/cs unknown
- 2002-05-24 EP EP02754586A patent/EP1392364B1/en not_active Expired - Lifetime
- 2002-05-24 PL PL02366903A patent/PL366903A1/xx not_active Application Discontinuation
- 2002-05-24 UA UA20031210980A patent/UA79091C2/uk unknown
- 2002-05-24 HU HU0401308A patent/HUP0401308A2/hu unknown
- 2002-05-24 RU RU2003137568/15A patent/RU2301056C2/ru not_active IP Right Cessation
-
2003
- 2003-11-25 US US10/722,334 patent/US20040126333A1/en not_active Abandoned
- 2003-12-08 HR HR20031016A patent/HRP20031016A2/xx not_active Application Discontinuation
- 2003-12-19 BG BG108480A patent/BG108480A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2003137568A (ru) | 2005-06-10 |
| SK15832003A3 (sk) | 2004-08-03 |
| HUP0401308A2 (hu) | 2004-11-29 |
| RU2301056C2 (ru) | 2007-06-20 |
| BG108480A (bg) | 2004-12-30 |
| HRP20031016A2 (en) | 2005-10-31 |
| ATE533511T1 (de) | 2011-12-15 |
| EP1392364B1 (en) | 2011-11-16 |
| WO2002098464A2 (en) | 2002-12-12 |
| EP1262172A1 (en) | 2002-12-04 |
| PL366903A1 (en) | 2005-02-07 |
| US20040126333A1 (en) | 2004-07-01 |
| CZ20033541A3 (cs) | 2004-05-12 |
| WO2002098464A3 (en) | 2003-03-20 |
| EP1392364A2 (en) | 2004-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA79091C2 (en) | Liquid polymer composition for prevention and treatment of the oral cavity diseases | |
| EP0404558B1 (en) | Liquid polymer composition, and method of use | |
| US5438076A (en) | Liquid polymer composition, and method of use | |
| JP2022164947A (ja) | 高張性抗微生物治療用組成物 | |
| US20200054667A1 (en) | Periodontal gel composition and method of use | |
| Costa et al. | Should local drug delivery systems be used in dentistry? | |
| Alpan et al. | Ozone in dentistry | |
| Arunachalam et al. | Perioceutics in the management of Periodontal Disease | |
| US9861646B2 (en) | Dental compositions | |
| JP2002128697A (ja) | 口腔治療予防剤 | |
| JPH05201878A (ja) | 歯周炎処置用医薬製剤 | |
| IT201900018752A1 (it) | Composizione a base di olii essenziali ad uso odontoiatrico per il trattamento della periodontite e della mucosite perimplantare | |
| ES2647125T3 (es) | Sistema de liberación oral | |
| Thakur et al. | Comparative evaluation of post-operative pain with different calcium hydroxide formulations when used as intracanal medicament in root canal treatment-In vivo study | |
| JPS63303922A (ja) | 根管治療剤 | |
| US20210154104A1 (en) | Substances and methods for bedside management of post-operative pain | |
| RU2269974C2 (ru) | Способ лечения пародонтита | |
| ITFI20140116A1 (it) | Composizione ad uso odontoiatrico per il trattamento delle tasche paradontali | |
| Mythili et al. | Non-Surgical Periodontal Therapy--A Fundamental Approach | |
| UA131174U (uk) | Спосіб лікування хронічного верхівкового періодонтиту | |
| EP1500389A1 (en) | Biofilm removing agent | |
| WO2004000253A1 (en) | Improved pharmaceutical dental formulations | |
| Anusha Rajagopalan | Effectiveness of Metronidazole as Local Drug Delivery in Periodontal Diseases–A Review | |
| Özüdoğru | The Use of Silver Compounds in Dentistry | |
| CA2008772A1 (en) | Oral antifungal preventative, and method of use |